Patents by Inventor Ross FRASER

Ross FRASER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12319924
    Abstract: The present invention relates to promoters that function specifically or preferentially in the liver. These promoters are capable of enhancing liver-specific expression of genes. The invention also relates to expression constructs, vectors and cells comprising such liver-specific promoters, and to methods of their use. The present invention future relates to adeno-associated virus (AAV) gene therapy vectors comprising the liver-specific promoters, therapeutic agents comprising the liver-specific promoters, and methods using the same.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: June 3, 2025
    Assignee: uniQure IP B.V.
    Inventors: Jacek Lubelski, David Johannes Francois Du Plessis, Ying Pui Liu, Olivier Ter Brake, Juan Manuel Iglesias Gonzalez, Ross Fraser, Michael Roberts
  • Patent number: 12241115
    Abstract: The present invention relates to methods of enriching target single-stranded nucleic acids in a mixed population of single-stranded nucleic acids. The method involves protecting the target single-stranded nucleic acids and using a 5? exonuclease to digest the non-target single-stranded nucleic acids. The invention also relates to methods of cloning target single-stranded nucleic acids into vectors, and to associated compositions and kits.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: March 4, 2025
    Assignee: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventors: Anne Braae, Juan Manuel Iglesias Gonzalez, Joanna Critchley, Michael Roberts, Ross Fraser
  • Publication number: 20230340460
    Abstract: The present invention provides a plurality of synthetic nucleic acid comprising (a) a nucleic acid sequence containing at least one unique regulatory element (URE); wherein the URE comprises at least one regulatory element and a plurality of unique barcodes associated with the at least one regulatory element; and (b) a nucleic acid sequence encoding an transcribable reporter sequence, wherein each barcode is between 12-35 nucleotides in length and have a GC content between 25-65%. URE can be one regulatory element or a combination of regulatory elements. Libraries of expression vectors and plasmids expressing the plurality of synthetic nucleic acids are also provided herein. Additional aspects described herein are methods for identifying the strength of a unique regulatory element in vivo or in vitro using the synthetic nucleic acids or libraries expressing the same.
    Type: Application
    Filed: December 23, 2020
    Publication date: October 26, 2023
    Applicant: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventors: Michael L. Roberts, Thomas Waibel, Ross Fraser, Joanna Critchley, Kerstin Brzezek
  • Publication number: 20230056396
    Abstract: The technology described herein is directed to systems and methods for synthetic regulatory sequence design or production. In several aspects described herein are methods of designing and optionally synthesizing shortened or otherwise modified polynucleotide sequences from polynucleotide sequences with transcriptional regulatory functionality. In other aspects described herein are isolated nucleic acid modules and viral vectors, comprising said shortened or otherwise modified polynucleotide as designed or synthesized herein.
    Type: Application
    Filed: January 15, 2021
    Publication date: February 23, 2023
    Applicant: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventors: Kira MOURAO, Michael L. ROBERTS, Ross FRASER
  • Publication number: 20230037026
    Abstract: The present invention provides a method of identifying the strength of one or more unique regulatory elements (URE) having conformational effect on a transcribable reporter sequence.
    Type: Application
    Filed: December 23, 2020
    Publication date: February 2, 2023
    Applicant: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventors: Michael L. Roberts, Richard Jude Samulski, Thomas Waibel, Ross Fraser, Joanna Critchley, Kerstin Brzezek
  • Publication number: 20220073943
    Abstract: The present invention relates to promoters that function specifically or preferentially in the liver. These promoters are capable of enhancing liver-specific expression of genes. The invention also relates to expression constructs, vectors and cells comprising such liver-specific promoters, and to methods of their use. The present invention future relates to adeno-associated virus (AAV) gene therapy vectors comprising the liver-specific promoters, therapeutic agents comprising the liver-specific promoters, and methods using the same.
    Type: Application
    Filed: May 14, 2021
    Publication date: March 10, 2022
    Inventors: Jacek LUBELSKI, David Johannes Francois DU PLESSIS, Ying Poi LIU, Olivier TER BRAKE, Juan Manuel IGLESIAS GONZALEZ, Ross FRASER, Michael ROBERTS
  • Publication number: 20220009981
    Abstract: The present invention relates to regulatory nucleic acid sequences, in particular liver-specific cis-regulatory elements, cis-regulatory modules, promoters and other such nucleic acid sequences, that are capable of enhancing liver-specific expression of genes. The invention also relates to expression constructs, vectors and cells comprising such liver-specific regulatory nucleic acid sequences, and to methods of their use. The liver-specific regulatory nucleic acid sequences are of particular utility for gene therapy applications, but also find utility in other areas such as bioprocessing and biotechnology.
    Type: Application
    Filed: November 19, 2019
    Publication date: January 13, 2022
    Applicant: SYNPROMICS LIMITED
    Inventors: Michael ROBERTS, Juan Manuel IGLESIAS, Jorge Omar YANEZ-CUNA, Nicolle KIPPEN, Ross FRASER, Katie BAKER
  • Publication number: 20210180111
    Abstract: The present invention relates to methods of enriching target single-stranded nucleic acids in a mixed population of single-stranded nucleic acids. The method involves protecting the target single-stranded nucleic acids and using a 5? exonuclease to digest the non-target single-stranded nucleic acids. The invention also relates to methods of cloning target single-stranded nucleic acids into vectors, and to associated compositions and kits.
    Type: Application
    Filed: February 25, 2019
    Publication date: June 17, 2021
    Applicant: ASKLEPIOS BIOPHARMACEUTICAL,INC.
    Inventors: Anne BRAAE, Juan Manuel Iglesias GONZALEZ, Joanna CRITCHLEY, Michael ROBERTS, Ross FRASER